HealthDay News — Clascoterone cream, 1%, appears to be safe and effective for the treatment of acne, according to a study published online April 22 in JAMA Dermatology.

Adelaide Hebert, MD, from the University of Texas Health Science Center in Houston, and colleagues assessed the safety and efficacy of clascoterone cream, 1%, a novel topical androgen receptor inhibitor, in 2 phase 3 clinical trials (including a total 1,440 patients) in which patients were randomly assigned to clascoterone cream, 1%, or a vehicle cream.

The researchers found that at week 12, the treatment success rates with clascoterone cream were 18.4 and 20.3% versus 9 and 6.5% with vehicle creams, respectively. In both intervention groups at week 12, there was a significant reduction in absolute noninflammatory lesions from baseline to −19.4 vs −13 and −10.8 with the vehicle cream, respectively. Similarly, there was a reduction in inflammatory lesions from baseline in the 2 intervention groups of −19.3 and −20 vs −15.5 and −12.6 with vehicle cream, respectively. The predominant adverse reaction was trace or mild erythema, but rates were low.

Related Articles

“Clascoterone cream, 1%, is under consideration as a first-in-class therapeutic agent for acne treatment, potentially providing an alternative to antibiotics and/or offering an adjunct treatment to existing combination acne therapies, including retinoids,” the authors write.


Continue Reading

Several authors disclosed financial ties to pharmaceutical companies, including Cassiopea, which manufactures clascoterone and funded the study.

Abstract/Full Text

Editorial